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Abstract
Background: Unlike in HIV-1 infection, the majority of HIV-2 patients produce broadly reactive neutralizing antibodies,
control viral replication and survive as elite controllers. The identification of the molecular, structural and evolutionary
footprints underlying these very distinct immunological and clinical outcomes may lead to the development of new
strategies for the prevention and treatment of HIV infection.
Methodology/Principal Findings: We performed a side-by-side molecular, evolutionary and structural comparison of the
C2, V3 and C3 envelope regions from HIV-1 and HIV-2. These regions contain major antigenic targets and are important for
receptor binding. In HIV-2, these regions also have immune modulatory properties. We found that these regions are
significantly more variable in HIV-1 than in HIV-2. Within each virus, C3 is the most entropic region followed by either C2
(HIV-2) or V3 (HIV-1). The C3 region is well exposed in the HIV-2 envelope and is under strong diversifying selection
suggesting that, like in HIV-1, it may harbour neutralizing epitopes. Notably, however, extreme diversification of C2 and C3
seems to be deleterious for HIV-2 and prevent its transmission. Computer modelling simulations showed that in HIV-2 the
V3 loop is much less exposed than C2 and C3 and has a retractile conformation due to a physical interaction with both C2
and C3. The concealed and conserved nature of V3 in the HIV-2 is consistent with its lack of immunodominancy in vivo and
with its role in preventing immune activation. In contrast, HIV-1 had an extended and accessible V3 loop that is consistent
with its immunodominant and neutralizing nature.
Conclusions/Significance: We identify significant structural and functional constrains to the diversification and evolution of
C2, V3 and C3 in the HIV-2 envelope but not in HIV-1. These studies highlight fundamental differences in the biology and
infection of HIV-1 and HIV-2 and in their mode of interaction with the human immune system and may inform new vaccine
and therapeutic interventions against these viruses.
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Introduction
Human Immunodeficiency Virus type 1 (HIV-1) infection affects
more than 40 million individuals throughout the world. It is caused
mainly by isolates belonging to group M. Within this group there
are nine different subtypes named A to H, six subsubtypes (F1, F2,
A1–A4) and at least thirty six recombinant forms named CRF01 up
to CRF36 [1]. In contrast to the HIV-1 pandemic, HIV-2 is only
prevalent in West Africa where it seems to have been present since
the 1940s [2]. In Europe infection with HIV-2 remains rare (2–3%
of all AIDS cases), being observed mainly in France and Portugal
[3,4,5]. Eight different HIV-2 groups named A through H have
been reported but only groups A and B cause human epidemics
[6,7,8,9]. Isolates from group A are, however, responsible for the
vast majority of HIV-2 infections worldwide [10].
For reasons that are still not clear, HIV-1 and HIV-2 infections
lead to very different immunological and clinical outcomes. In
contrast to HIV-1 infected patients, the majority of HIV-2-
infected individuals have reduced general immune activation,
normal CD4+ T cell counts, low or absent viremia and absence of
clinical disease [11,12,13,14]. This may be related with a more
effective immune response produced against HIV-2. In fact, most
HIV-2 infected individuals have strong cytotoxic responses to Env
and Gag proteins and raise autologous and heterologous
neutralizing antibodies [3,15,16,17,18]. The attenuated course of
HIV-2 infection compared to HIV-1 has also been associated to a
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14548lower state of immune activation, which may be related to the
immunosuppressive activity of the C2-V3-C3 envelope region
[19,20,21]. Similar immunosuppressive activity has not been
found in the homologous C2-V3-C3 region in the HIV-1 envelope
[19]. Finally, the transmission rate of HIV-2 is also significantly
lower than that of HIV-1 and this has been associated with the low
or absent viremia found in most HIV-2 patients [22,23].
The HIV-1 Env glycoprotein is a trimer on the virion surface
with extensive N-linked glycosylation that effectively shields many
conserved epitopes from antibody recognition [24]. It is composed
of trimers of a surface (SU) glycoprotein with a molecular weight of
120–125 kDa (gp120–125) that is bound to a transmembrane
(TM) glycoprotein with 36–41 kDa (gp36–41). SU can be divided
into five hipervariable regions, named V1 to V5, bordered by five
conserved regions, named C1 to C5. The C2 and C3 regions
associate to form the CD4 binding site such that mutations in
amino acid at positions 267Q in C2 and 368R in C3 abrogate
gp120 binding to CD4 [25,26]. In HIV-1, V3 is one of the most
important determinants of viral tropism and co-receptor usage
[27,28]. This region also contains major antigenic and neutralizing
epitopes in HIV-1 which are well exposed upon CD4-binding
[29,30,31,32,33,34,35]. Although still debatable, the V3 region in
HIV-2 may also contain broadly neutralizing epitopes
[36,37,38,39,40,41,42]. However, in contrast to HIV-1, the V3
and flanking C2 and C3 regions are not immunodominant in
HIV-2 infected patients [43,44,45,46]. Moreover, it remains to be
determined whether these regions are exposed or concealed in the
envelope complex of primary isolates of HIV-2.
In HIV-1 infection escape from antibody neutralization occurs
frequently and is the major driving force of the molecular
evolution of the envelope glycoproteins [47,48]. Not surprisingly,
codons under diversifying selection (positive selection) seem to be
clustered mostly in the hypervariable V1/V2 and V3 regions that
contain important and accessible neutralizing targets [49,50]. The
impact of the neutralizing antibody response in the in vivo evolution
of the HIV-2 Env is currently unknown.
The present study was designed to identify molecular and
evolutionary features of the C2, V3 and C3 regions in HIV-1 and
HIV-2 infected patients that could be related with their different
immunological and clinical outcomes. We describe some poten-
tially important differences in the genetic constitution, molecular
evolution and conformation of the C2, V3 and C3 regions in HIV-
1 and HIV-2 that provide new insights into their function and may
inform the design of HIV vaccines.
Results
HIV-1 is significantly more variable in the envelope C2, V3
and C3 regions than HIV-2
We compared the inter-patient genetic diversity of HIV-1 and
HIV-2 in two different datasets: HIV-1 group M (all subtypes) and
HIV-2 group A sequences from all over the world (Control dataset
composed of reference sequences) and newly derived HIV-1 and
HIV-2 sequences obtained from Portuguese (PT) patients. Phyloge-
netic analysis showed that HIV-1 sequences circulating in Portugal
belong to different subtypes and recombinant forms (Figure S1A).
Forty five sequences were subtype B and six belonged to the
recombinant form CRF14_BG. Subtypes G (4 sequences) and C (2),
sub-subtype F1 (2), and CRF02_AG (1) were also found. Regarding
HIV-2, allsequences from Portugal clustered together within group A
(Figure S1B). Collectively, these results are consistent with previous
studies showing a highly complex HIV epidemics in Portugal caused
exclusively by HIV-2 group A and different subtypes of HIV-1 group
M [51,52,53,54]. Nucleotide diversity between HIV-1 viruses found
in Portugal was significantly higher compared to HIV-2 (mean
number of substitutions per site, 0.336, 95%CI [0.329; 0.342] vs
0.239, [0.236; 0.243], P,0.0001). Similar results were found for the
HIV-1 and HIV-2 Control datasets (Table S1). Hence, we conclude
that HIV-1 is genetically more diverse than HIV-2 in the envelope
region comprising C2, V3 and C3.
Amino acid diversity in the C2, V3 and C3 regions of HIV-1
and HIV-2 were compared by calculating Shannon’s entropy [55].
Mean entropy values for the three regions were significantly higher
in HIV-1 than in HIV-2 both in PT (0.794 vs 0.409, P,0.0001)
and Control datasets (0.702 vs 0.353, P,0.0001) confirming that
these regions are more variable in HIV-1 than in HIV-2. Entropy
was also significantly higher in HIV-1 than in HIV-2 in each
separate region (C2, P,0.05; V3, P,0.005; C3, P,0.0005) of PT
sequences. The region with higher mean entropy was C3 in both
viruses (1.031, 95%CI [0.845, 1.217] for HIV-1 vs 0.534, 95%CI
[0.378, 0.689] for HIV-2, P,0.0005) followed by V3 (0.674,
[0.506, 0.841]) and C2 (0.574, [0.427, 0.721]) in HIV-1 and C2
(0.326, [0.175, 0.477]) and V3 (0.304, [0.176, 0.433]) in HIV-2
(Figure 1). Comparable results were obtained for the Control
datasets but in this case V3 was the least entropic region both in
HIV-1 and HIV-2 (Table S1 and Figure S2). Not surprisingly,
amino acids with higher entropy (values above 1) were primarily
located in the C3 region of both viruses and there were more
highly entropic amino acids in C3 in HIV-1 than in HIV-2 both in
the PT and Control datasets (PT dataset: 51.9% in HIV-1 vs
24.5% in HIV-2; Control dataset: 35.3% in HIV-1 vs 20.8% in
HIV-2). Notably, the amino acids in V3 that are related with co-
receptor usage, positions 11/25 in HIV-1 (codons 306/320)
[56,57] and possibly positions 18/19/27 in HIV-2 (codons 319/
320/328) [17,58], had a high entropy score in both viruses.
The mean number of potential N-linked glycosylation sites both
in HIV-1 and HIV-2 sequences from Portugal was 7 (range: 4–9 in
HIV-1; 5–9 in HIV-2). The most conserved glycosylation sites
were located in C2 in both viruses (Figure 2). Nonetheless, in this
region, there were four highly conserved glycosylation sites in
HIV-2 (present in $80% of strains) and only two such sites in
HIV-1. With the exception of the highly conserved site located in
the beginning of C3 in HIV-1, glycosylation sites found in C3
varied from strain to strain in number and location, this being
more evident in HIV-1 than in HIV-2. In V3 there were two
highly conserved glycosylation sites in both viruses. Similar
observations were made for HIV-1 and HIV-2 sequences in the
Control datasets (Table S1 and Figure S3).
Selective pressures act differently in HIV-1 and HIV-2
We have recently found that HIV-2 displays a faster
evolutionary rate in the envelope gp125 and C2-V3-C3 region
than HIV-1 in patients with chronic and advanced disease [52,59].
The faster evolutionary rate in HIV-2 was more pronounced in
synonymous sites than in non-synonymous sites suggesting a
weaker positive selection in HIV-2 than in HIV-1. To investigate
this possibility, we analysed diversifying selection in the C2-V3-C3
region of both viruses using codon-based models of molecular
evolution. Firstly, we estimated the ratio of non-synonymous and
synonymous substitution rates (dN/dS ratio) averaged over all
sites. For HIV-1 sequences from Portugal dN/dS ratio was 0.703,
95%CI [0.668, 0.740]; for HIV-2 it was 0.451, [0.419, 0.484].
Similar values were obtained for the Control alignments (Table
S1). These results are consistent with the higher degree of genetic
conservation of the C2, V3 and C3 regions in HIV-2.
Site-by-site analysis revealed that diversifying selection is unevenly
distributed along the studied region between the two viruses (PT,
P,0.001; Controls, P,0.001) (Figures 3 and S4). For HIV-2
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selected (PS) sites depending on the method that was used (SLAC/
FEL/REL) while for HIV-1 the number of sites ranged from 7 to 17
(Table 1). Taking into account only sites that were selected by at least
two methods, HIV-2 had a total of 7 PS sites whereas in HIV-1 there
were 9 sites. The sites were distributed as follows: in C2 there were 3
sites in HIV-2 and 2 in HIV-1; in V3 there were 2 sites in HIV-1, and
n os i t e si nH I V - 2 ;i nC 3t h e r ew e r e4s i t e si nH I V - 2a n d5i nH I V - 1 ,
including one codon within the CD4 binding site (codon 378 in HIV-
1) and two in the a2-helix (codons 343 and 346) [60]. In Control data
sets the number of PS sites was slightly lower but they were similarly
distributed, with the exception of the V3: 1 PS site in HIV-2, but no
sites in HIV-1 (Tables S1 and S2). Importantly, we found that when
compared to HIV-1, positive selection was stronger in HIV-2 inmost
sites (Tables 1 and S2).
The comparison of diversifying selection between terminal and
internal branches of the phylogenetic trees revealed two distinct
profiles for HIV-1 and HIV-2. Firstly, non-synonymous substitu-
tion rates were significantly different between the internal nodes
and the tips of the tree in all datasets: PT, P=0.002 for HIV-2 and
P=0.011 for HIV-1; Controls, P,0.001 and P=0.004 (data not
shown). Stronger selection was in general found at codons selected
simultaneously at the tips and the external branches of the HIV-1
and HIV-2 trees. Importantly, however, only 2 of the 7 sites (29%)
detected in terminal branches of PT HIV-2 tree were also under
positive selection along the internal branches (codons 267 and 270
in C2). In contrast, for HIV-1 most positively selected sites (6/9,
67%) were present both in the internal and the terminal branches.
In Control datasets these percentages were 43% for HIV-2 and
71% for HIV-1 (Table S2). These results suggest that natural
selection affects less the transmission fitness of HIV-1 than HIV-2.
Structure and solvent accessibility of V3 differ in HIV-1
and HIV-2
A model of the structure of the C2-V3-C3 region was built for
HIV-1 and HIV-2 based on the atomic coordinates of the HIV-1
gp120 and SIV gp120 using consensus sequences from both the PT
and Control HIV-1 and HIV-2 alignments. For HIV-1, the
Figure 1. Shannon’s entropy of individual amino acids in the C2, V3 and C3 envelope regions in HIV-1 and HIV-2. (A) HIV-1 alignment
(PT dataset), sites were numbered according to codon env position of HIV-1 HXB2 reference strain; (B) HIV-2 alignment (PT dataset), sites were
numbered according to codon env position of HIV-2 ALI reference strain.
doi:10.1371/journal.pone.0014548.g001
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having only a slight difference in V3, which presents less regular
secondary structure in the PT sequence (Figure S5). For HIV-2, the
structures of PT and Control sequences were identical. The
structure of the C2-V3-C3 region was however markedly different
between HIV-1 and HIV-2, the most striking differences being the
significant retraction of the V3 loop in HIV-2 and its potential
interaction both with C2 and C3 (Figure 4A). Identical results were
obtained when comparing the HIV-1 and HIV-2 control sequences
(Figure S6). The predicted non-covalent interaction between V3,
C3 and C3 in HIV-2 involves residues Tyr296 and His301 in C2
binding, respectively, to Arg331 and Trp334 in V3, and Phe337 in
C3 binding to Phe321 in V3 (Figure 4B).
The solvent accessibilities of amino acid residues were also
calculated for both models (Figure 5). As expected, both in HIV-1
and HIV-2 most PS sites and N-glycans had at least 50% surface
exposure. In HIV-2, 8 out of 37 (22%) amino acids in C2, 8/34
(24%) in V3 and 19/53 (36%) in C3 were highly exposed ($70%
solvent accessibility) whereas in HIV-1 these were 9/37 (24%), 15/
35 (43%) and 10/52 (19%), respectively. Consistent with the high
exposure of the V3 region in HIV-1, the two amino acids at
positions 306 and 320 involved in binding to co-receptors were well
exposed ($50% solvent accessibility). In contrast, in HIV-2, among
amino acids 319/320 and 328 in V3 loop potentially involved in co-
receptor binding, only 319 was relatively well exposed. Despite the
potential interaction between V3 and C3 (Figure 4B), the overall
exposition of C3 was higher in HIV-2 than in HIV-1. Thus, for
instance, 42% (5/12) of the residues in C3 that may contribute for
the formation of the CD4-binding site (positions 377–388) in HIV-2
showed high solvent accessibility. In HIV-1 only 3 out of 16 (19%)
amino acids with similar function (positions 367–382) were highly
exposed. Similar results were obtained when comparing the HIV-1
and HIV-2 control sequences (Figure S7).
Discussion
To investigate the molecular and structural features underlying
the differences in HIV-1 and HIV-2 biology and human infection,
Figure 2. Frequency of N-glycosylation sites in the C2, V3 and C3 envelope regions in HIV-1 and HIV-2. (A) HIV-1 alignment (PT dataset),
sites were numbered according to codon env position of HIV-1 HXB2 reference strain; (B) HIV-2 alignment (PT dataset), sites were numbered
according to codon env position of HIV-2 ALI reference strain.
doi:10.1371/journal.pone.0014548.g002
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significant number of HIV-1 and HIV-2 infected patients living
in Portugal and worldwide. HIV-2 sequences from Portugal
belonged to group A and the majority of HIV-1 sequences
belonged to subtype B (75%) followed by subtypes G, C and F,
CRF02_AG and CRF14_BG. Collectively, these results are
consistent with previous studies showing a highly complex HIV
epidemic in Portugal caused by HIV-2 group A and different
subtypes of HIV-1 group M [44,51,52,53,54,61,62].
Genetic distances and amino acid diversity between HIV-1
viruses were significantly higher compared to HIV-2. This was
surprising since at the individual level HIV-2 displays a similar
[52] or even faster evolutionary rate than HIV-1 in the C2-V3-C3
region [59]. The more pronounced evolutionary rate in synony-
mous sites than in non-synonymous sites in HIV-2 [59] together
with the rare escape of this virus from autologous neutralizing
antibodies [17], suggested that the lower amino acid diversity in
HIV-2 could be related with a weaker positive selection or even
with negative selection [62]. This was not the case however since
most sites in C2 and C3 were under stronger positive selection in
HIV-2 than in HIV-1. The C3 region of HIV-1 is antibody
accessible [63] and is subject to diversifying selection because it is a
major neutralizing target [64,65,66,67]. Therefore, the high level
of positive selection detected in C3 together with its high solvent
exposure strongly suggests that this region is also antibody
accessible in HIV-2 and might be a major neutralizing domain.
Strength of selection was significantly different between internal
and external branches of the HIV-1 and HIV-2 phylogenetic trees.
This is expected in populations of highly variable RNA viruses and
implies that non-synonymous substitutions can be highly delete-
rious [68,69]. In HIV-1, most of the codons selected in the tips of
the tree were also under selection along the internal branches,
indicating that adaptation in these sites is occurring at the host and
population levels [68]. In contrast, most adaptive mutations in
HIV-2 were only found in the tips of the tree indicating that they
are recent maladaptive substitutions that are transitory at the
Figure 3. Positive selection in the C2, V3 and C3 envelope regions in HIV-1 and HIV-2. dN-dS values were estimated by FEL and scaled by
the total codon tree length. (A) HIV-1 alignment (PT dataset), sites were numbered according to codon env position of HIV-1 HXB2 reference strain; (B)
HIV-2 alignment (PT dataset), sites were numbered according to codon env position of HIV-2 ALI reference strain.
doi:10.1371/journal.pone.0014548.g003
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tion of C2 and C3 in HIV-2 seems to have a dominant negative
effect on viral fitness and transmission. This data suggests that one
possible consequence of the unexpectedly high evolutionary rate of
HIV-2 at the patient level can be the frequent accumulation of
deleterious mutations and production of defective viruses
[52,59,71]. A high frequency of defective viruses in HIV-2
infected individuals could explain the poor replication of this virus
in vivo as well as its very low transmissibility.
Unlike in HIV-1, the V3 loop in HIV-2 always presented the
lower amino acid diversity. This result might be a consequence of
significant structural and conformational constraints due to its role
in preventing chronic and disruptive immune activation [20] and
in co-receptor binding [58]. On the other hand, these results imply
that the V3 loop is not well exposed in the HIV-2 envelope
complex in vivo. Indeed, by computer modelling simulations we
show that in HIV-2 the V3 loop is much less exposed than C2 and
C3 and likely has a retractile conformation due to non-covalent
interaction both with C2 and C3. In contrast, HIV-1 had, as
previously found, an extended and highly accessible V3 loop
[66,67,72]. Such conformation is entirely consistent with its
immunodominant and neutralizing nature and with its crucial role
in HIV-1 co-receptor binding and tropism [33,34,35,73,74,75].
Conversely, the concealed nature of V3 in the HIV-2 envelope
complex implies that this region may not be immunodominant in
HIV-2 infection. Indeed, a significant number of HIV-2 patients
do not raise antibodies against the V3 loop [43] or against a
polypeptide comprising the C2, V3 and C3 regions [45]. Thus, the
occlusion of V3 in the HIV-2 envelope complex may prevent it
from over immune recognition and associated sequence changes
thereby preserving its crucial functions in viral entry. It has been
shown that removal or antigenic dampening of the HIV-1 V3 loop
redirects the neutralizing immune response to other epitopes of the
Env protein that otherwise would be non-neutralizing or non-
antibody responsive [33,76,77,78]. In this context, the occluded
nature of the V3 region in the HIV-2 envelope complex might
favour a more effective production of broadly neutralizing
antibodies targeting other regions in gp125 such as the C2, V1,
V2, V4 and C5 regions [37,38,39,79].
In conclusion, the C2 and C3 regions are well exposed in the HIV-
2 envelope complex and are under strong diversifying selection
suggesting that, like in HIV-1, they may harbour neutralizing
epitopes. However, extreme diversification of C2 and C3 in HIV-2
seems to be deleterious for the virus and prevent its transmission. On
the other hand, V3 is highly conserved in HIV-2 and is concealed
within the envelope complex, possibly due to a physical interaction
with C2 and C3. In contrast, V3 is highly exposed and variable in
HIV-1 whichis consistent with its immunodominant and neutralizing
properties. Collectively, we identify significant structural and
functional constrains to the diversification and evolution of C2, V3
and C3 in the HIV-2 envelope but not in HIV-1. These studies
highlight fundamental differences in the biology and infection of
HIV-1 and HIV-2 and in their mode of interaction with the human
immune system and may inform new vaccine and therapeutic
interventions against these viruses.
Materials and Methods
Amplification, cloning and sequencing of HIV-1 and HIV-
2 viruses from Portugal
Portuguese (PT) samples were collected from HIV infected
patients, followed in hospitals in the North and South of Portugal
Figure 4. Conformational structure of C2, V3 and C3 envelope regions in HIV-1 and HIV-2. The conformational structure of consensus
amino acid sequences derived from the PT datasets was obtained by homology modeling as indicated in Material and Methods. In the schematics, C2
is shown in red, V3 in yellow and C3 in blue. (A) Balls represent the amino acids under positive selection. The red balls represent codons selected
simultaneously by SLAC, FEL and REL methods, while green balls stand for codons selected by at least two of these methods; (B) Model structure
showing the predicted interactions between V3, C2 and C3 in HIV-2 gp125. The non-covalent interaction involves residues Tyr296 and His301 in C2
binding, respectively, to Arg331 and Trp334 in V3, and Phe337 in C3 binding to Phe321 in V3.
doi:10.1371/journal.pone.0014548.g004
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counts. HIV-2 samples were collected between 1997 and 2005 from
49 patients, some of whom were infected in late-1970s [52,80].
HIV-1 samples were collected from 60 patients between 1993 and
1998.
Proviral DNA was extracted from uncultured PBMCs, or viral
genomic RNA was extracted from plasma and reverse transcribed. A
nested PCR technique was used to amplify a 373 bp HIV-2 C2-V3-
C3 env gene region and a 409 pb HIV-1 C2-V3-C3 env region as
described elsewhere [62,81]. PCR products weresequenced using the
BigDye Terminator Cycle sequencing kit (Applied Biosystems) and
an automated capillary sequencer (ABI PRISM 310, Applied
Biosystems). Newly derived HIV-1 sequences from Portugal have
been assigned GenBank accession numbers: EU335962 - EU335903.
Newly derived HIV-2 sequences from Portugal have been assigned
GenBank accession numbers: AY913773-AY913794, AY649545-
AY649554 and GU591163.
Additionally, 16 HIV-2 consensus sequences from a previous
publication [52] were also included in this study. The samples used
to obtain these consensus sequences were: 03PTHCC1,
03PTHCC2, 03PTHCC4, 03PTHCC5, 03PTHCC7, 03PTH-
CC8, 03PTHCC12, 05PTHCC13, 03PTHCC14, 03PTHCC17,
03PTHCC19, 03PTHSM2, 05PTHSM3, 03PTHSM7, 03PTH-
SM9 and 03PTHSM10.
Control datasets
As Control datasets to this study, HIV-1 group M (all subtypes)
reference sequence alignment (94 sequences) was obtained from
the Los Alamos HIV database (http://www.hiv.lanl.gov/). HIV-2
group A reference sequence alignment was also obtained from the
Los Alamos HIV database. Additional C2-V3-C3 sequences
derived from group A primary isolates were retrieved from the
Los Alamos Database adding to a total of 59 HIV-2 Control
sequences. Both control alignments are available as supplementary
information (Alignment S1 and S2).
Molecular and phylogenetic analysis
Nucleotide sequences were aligned using ClustalX 1.8 [82].
Maximum likelihood analyses were performed using the best-fit
models of molecular evolution estimated by Modeltest [83]. These
Figure 5. Solvent accessible surface area, positive selection and potential N-glycosylation sites in C2-V3-C3 region. (A) HIV-1
alignment (PT dataset), sites were numbered according to codon env position of HIV-1 HXB2 reference strain; (B) HIV-2 alignment (PT dataset), sites
were numbered according to codon env position of HIV-2 ALI reference strain. Coloured bars represent the amino acids under positive selection and
have the same colours (red and green) as the corresponding positions (balls) highlighted in Figure 4A. The dark blue stars over the bars correspond to
potential N-glycosylation sites conserved along the alignment (present in $50% of strains), whereas the light blue stars represent sites only present
in less than 50% of sequences.
doi:10.1371/journal.pone.0014548.g005
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PT HIV-1 and for HIV-1 and HIV-2 Control datasets [85].
Evolutionary distances were estimated under these models using
PAUP version 4.0 [86]. Tree searches were also conducted in
PAUP version 4.0 using either nearest-neighbor interchange (NNI)
or subtree pruning-regrafting (SPR) heuristic strategies, with
bootstrap resampling. All positions containing gaps and missing
data were eliminated from the dataset. In the final datasets there
were a total of 369 nucleotide positions in PT HIV-2 and 372
positions in PT HIV-1 alignments, and 369 positions in HIV-2
and HIV-1 Control alignments. Both alignments were tested for
recombination with the Single Breakpoint Recombination (SBP)
tool [87] in the DATAMONKEY web-server [88]; evidence for
recombination, inferred by the small sample AIC score, was only
found for HIV-1 Control dataset. Thus, when appropriate, a
multiple partition dataset was used for HIV-1 Control analysis.
Detection of N-linked glycosylation sites was performed with
Glycosite [89]. The entropy at each position in protein alignment
was measured with Shannon’s entropy [55].
Tests for codon selection
Selection pressures over the HIV-1 and HIV-2 C2-V3-C3
regions were examined with the HYPHY software package [90]
and the DATAMONKEY web-server [88]. All estimations were
performed using the MG94 codon substitution model [91] crossed
with the nucleotide substitution model previously selected with
Modeltest, GTR for PT HIV-2 and TVM for PT HIV-1 and
Control alignments. To understand if selection pressure within a
host is different from selection for transmission among hosts, non-
synonymous substitutions were compared between terminal and
internal branches of the phylogenetic tree, with the Test-
BranchDNDS.bf batch file in HyPHy, as described elsewhere [92].
Four different approaches were used to identify codons under
selection: single-likelihood ancestor counting (SLAC), fixed-effects
likelihood (FEL), internal fixed effects likelihood (IFEL) and relaxed-
effects likelihood (REL) methods [68,93]. While SLAC, FEL and
REL detect sites under selection at the external branches of the
phylogenetic three, IFEL identifies such sites only along the internal
branches. To classify a site as positively or negatively selected the cut-
off P-value was 10% for SLAC, FEL and IFEL. For REL, codons
under selection were detected with a cut-off value for the Bayes factor
of 50. Since SLAC, FEL and IFEL can estimate site-specific ratios of
non-synonymous and synonymous substitutions rates (dN/dS ratios)
as undefined or infinite due to dS =0, we reported dN-dS values
instead, which were scaled by the total codon tree length to allow a
better comparison between the two datasets. A multiple partition
dataset was used for the identification of codons under selection in
HIV-1 Control analysis. Site-by-site variation of synonymous
substitution rates can bias estimations of codon’s diversifying selection
[94]. Although all four methods described above model for this
variation, variation of synonymous rates from codon to codon in each
dataset was tested with the dNdSRateAnalysis.bf batch file in
HyPHy, as described elsewhere [92]. Finally, comparison of the dN/
dS distribution rates and the strength of selection between the HIV-1
and HIV-2 alignments, was performed with dNdSDistributionCom-
parison.bf batch file also in HyPHy, as described elsewhere [92].
Molecular modelling and calculation of solvent
accessible surfaces
Consensus amino acid sequences were derived for the different
HIV-1 and HIV-2 datasets. Structural models of HIV-1 and HIV-2
C2-V3-C3 were produced with SWISS-MODEL homology model-
lingserverinprojectmoderesortingtoSwiss-PdbViewer(DeepView)
version 4.0, using PDB file 2B4C (from HIV-1 JR-FL gp120) for
HIV-1, and PDB file 2BF1 (from SIV gp120) for HIV-2 as templates
[95,96,97,98]. Accelrys Discovery Studio Visualizer 2.5 [99] was used
to produce three dimensional images of the models obtained. Solvent
accessible surface area in A ˚ 2 was calculated by Gerstein’s calc-surface
software on UCSF Chimera [100,101] with a probe size of 1.4 A ˚.A l l
atoms in the input PDB file were included in the calculation. The
solvent accessible surface data was normalized dividing each amino
acid residue solvent accessible surface value added by the solvent
accessible surface value of the corresponding amino acid residue (X)
in the tripeptide Gly-X-Gly. The inter-chain H-Bonds formed by
HIV-2 V3 with C2 and C3 were calculated with H-Bond Finder
software on UCSF Chimera [100,101] with a probe size of 1.4 A ˚.A l l
atoms in the input PDB file were included in the calculation.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 4.0c for Macintosh (GraphPad Software, 2005, San Diego,
California, USA, www.graphpad.com) with a level of significance
of 5%. Non-parametric Mann-Whitney U test was used to
compare Shannon’s entropy values and nucleotide distances.
Supporting Information
Figure S1 Genotyping HIV-1(A) and HIV-2 (B) by maximum-
likelihood phylogenetic analysis. The phylogenetic trees were
constructed using the SPR heuristic search strategy and 1000
bootstrap replications, with reference sequences from HIV-1,
under the TVM+G+I evolutionary model (A) and with reference
sequences from HIV-2, under the GTR+G+I evolutionary model
(B). The bootstrap values (above 50%) supporting the internal
branches are shown. The scale bar represents evolutionary
distances in substitutions per site.
Found at: doi:10.1371/journal.pone.0014548.s001 (0.21 MB
PDF)
Figure S2 Shannon’s entropy of individual amino acids in the
C2, V3 and C3 envelope regions in HIV-1 and HIV-2. (A) HIV-1
alignment (Control dataset), sites were numbered according to
codon env position of HIV-1 HXB2 reference strain; (B) HIV-2
alignment (Control dataset), sites were numbered according to
codon env position of HIV-2 ALI reference strain.
Found at: doi:10.1371/journal.pone.0014548.s002 (0.96 MB TIF)
Figure S3 Frequency of N-glycosylation sites in the C2, V3 and
C3 envelope regions in HIV-1 and HIV-2. (A) HIV-1 alignment
(Control dataset). Sites were numbered according to codon env
position of HIV-1 HXB2 reference strain. (B) HIV-2 alignment
(Control dataset). Sites were numbered according to codon env
position of HIV-2 ALI reference strain.
Found at: doi:10.1371/journal.pone.0014548.s003 (0.58 MB TIF)
Figure S4 Positive selection in the C2, V3 and C3 envelope
regions in HIV-1 and HIV-2. dN-dS values were estimated by
FEL and scaled by the total codon tree length. (A) HIV-1
alignment (Control dataset). Sites were numbered according to
codon env position of HIV-1 HXB2 reference strain. (B) HIV-2
alignment (Control dataset). Sites were numbered according to
codon env position of HIV-2 ALI reference strain.
Found at: doi:10.1371/journal.pone.0014548.s004 (0.53 MB TIF)
Figure S5 Superimposition of the conformational structures
generated by homology modelling of Portuguese and Control C2,
V3 and C3 regions of HIV-1 and HIV-2. In the schematics,
Portuguese structures are represented in red, and Control structures
are in blue.
Found at: doi:10.1371/journal.pone.0014548.s005 (0.78 MB TIF)
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e14548Figure S6 Conformational structure of C2, V3 and C3 envelope
regions in HIV-1 and HIV-2. The conformational structure of
consensus amino acid sequences derived from the Control datasets
was obtained by homology modeling as indicated in ‘‘Materials and
Methods.’’ In the schematics, C2 is shown in red, V3 in yellow, and
C3 in blue. Balls represent the amino acids under positive selection.
(A) The red balls represent codons selected simultaneously by
SLAC, FEL and REL methods, while green balls stand for codons
selected by at least two of these methods. (B) Model structure
showing the predicted interactions between V3, C2 and C3 in HIV-
2 gp125. The non-covalent interaction involves residues Tyr296
and His301 in C2 binding, respectively, to Arg331 and Trp334 in
V3, and Phe337 in C3 binding to Phe321 in V3.
Found at: doi:10.1371/journal.pone.0014548.s006 (0.88 MB TIF)
Figure S7 Solvent accessible surface area, positive selection and
potential N-glycosylation sites in C2-V3-C3 region. (A) HIV-1
alignment (Control dataset). Sites were numbered according to
codon env position of HIV-1 HXB2 reference strain. (B) HIV-2
alignment (Control dataset). Sites were numbered according to
codon env position of HIV-2 ALI reference strain. Coloured bars
represent the amino acids under positive selection and have the
same colours (red and green) as the corresponding positions (balls)
highlighted in Figure S6. The dark blue stars over the bars
correspond to potential N-glycosylation sites conserved along the
alignment (present in $50% of strains), whereas the light blue stars
represent sites only present in less than 50% of sequences.
Found at: doi:10.1371/journal.pone.0014548.s007 (1.60 MB TIF)
Table S1 Summary of results for phylogenetic, codon selection
and solvent accessibility analysis for C2, V3 and C3 regions of
HIV-1 and HIV-2 Control datasets.
Found at: doi:10.1371/journal.pone.0014548.s008 (0.04 MB
DOC)
Table S2 Positively selected sites detected by SLAC, FEL, REL
and/or IFEL in Control HIV-1 and HIV-2 env C2, V3 and C3
regions.
Found at: doi:10.1371/journal.pone.0014548.s009 (0.10 MB
DOC)
Alignment S1 Alignment of HIV-1 reference sequences used as
a Control for the Portuguese HIV-1 dataset. Each sequence is
identified by the corresponding GenBank accession number.
Found at: doi:10.1371/journal.pone.0014548.s010 (0.04 MB
TXT)
Alignment S2 Alignment of HIV-2 sequences used as a Control
for the Portuguese HIV-2 dataset. Each sequence is identified by
the corresponding GenBank accession number.
Found at: doi:10.1371/journal.pone.0014548.s011 (0.02 MB
TXT)
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